AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Jul 12, 2022

Don't miss the latest from industry at the 2022 Innovation Academy!


Aad22 Crowd5

The Industry Non-CME (INC) Program at the 2022 AAD Innovation Academy is your chance to learn about the latest from industry. INC Programs take place before and after Innovation Academy sessions and events and are solely developed and delivered by the sponsor. INC programs do not qualify for continuing medical education (CME) credit.

Thursday, July 21

Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients with Refractory, Moderate to Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled with Other Systemic Drug Products

The goals of this program are to understand the burden of AD, to discuss the efficacy and safety of RINVOQ in patients with moderate to severe AD and to review resources available through RINVOQ Complete

When: Thursday, July 21 | 7:00 p.m. Registration | 7:30 p.m. Program

Where: Room 118/119/120, Vancouver Convention Centre

Friday, July 22

Artificial Intelligence, Clinical Decision Support, and the Future of Dermatology

Understanding how we can lead and advance care for our patients through technology is the focus of this presentation. Participants will gain an understanding of the relationship between clinical decision support, digital reference, and artificial intelligence.

Supported by: Janssen Pharmaceuticals

When: Friday, July 22 | 6:30 a.m. Program

Where: MacKenzie Ballroom | Fairmont Waterfront

View more information.

PsOphisTYKated Pathways: Understanding the Role of TYK2 in Psoriasis

When: Friday, July 22 | 7:30 p.m. Program

Where: Room 118/119/120, Vancouver Convention Centre

An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management

Alopecia areata is a common autoimmune disease characterized by hair loss that afflicts approximately 6.8 million individuals in the United States. Currently, there are no FDA-approved treatments for alopecia areata, although several treatments are used off-label to manage it. As the pathophysiology of alopecia areata is increasingly understood, novel therapies are becoming increasingly available.

Supported by: An educational grant from Pfizer Inc.

When: Friday, July 22 | 7:00 p.m. Registration & Meal | 7:30 p.m. Program

Where: MacKenzie Ballroom | Fairmont Waterfront

Saturday, July 23

Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

Join us for this PeerView MasterClass & Practicum in which a panel of PN experts will offer evidence-based, practical guidance on current diagnostic and treatment strategies, and the latest clinical data regarding novel therapies. Their discussion will be enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and the experience of treatment.

Supported by: An educational grant from Sanofi and Regeneron PharmaceuticalsWhen: Saturday, July 23 | 7:00 a.m. Registration & Breakfast | 7:30 a.m. ProgramWhere: MacKenzie Ballroom | Fairmont Waterfront

Interesting Stories
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
More in 2022 AAD Innovation Academy
Keira L. Barr, MD, FAAD
2022 AAD Innovation Academy
Unlocking the secrets of mind-body therapy
Jul 29, 2022
Robert T. Brodell, MD, FAAD
2022 AAD Innovation Academy
Fox Lecture: Access belongs to everyone
Jul 29, 2022
Img 9508
2022 AAD Innovation Academy
AAD debuts Innovation Academy in Vancouver
Jul 29, 2022
Edit Olasz Harken, MD, PhD, FAAD
2022 AAD Innovation Academy
Your name can be your skin care brand
Jul 29, 2022
Pearl E. Grimes, MD, FAAD
2022 AAD Innovation Academy
Kelly Lectureship traces advances in pigmentary diseases
Jul 29, 2022
Pearl Grimes, MD, FAAD, and Robert T. Brodell, MD, FAAD, FRCP
2022 AAD Innovation Academy
Saturday’s named lectureships take the stage
Jul 23, 2022
Jason B. Lee, MD, FAAD
2022 AAD Innovation Academy
How are your diagnostic skills?
Jul 23, 2022
Lindsay Strowd, MD, FAAD
2022 AAD Innovation Academy
Consultive dermatology plugs in post pandemic
Jul 23, 2022
Mehdi Rashighi, MD, FAAD
2022 AAD Innovation Academy
Game-changing new treatments evolve for dermatologic conditions
Jul 23, 2022
Carolyn Goh, MD, FAAD
2022 AAD Innovation Academy
New approaches to managing hair disorders
Jul 23, 2022
So Yeon Paek, MD, FAAD
2022 AAD Innovation Academy
Laser focused
Jul 22, 2022
Brett A. King, MD, PhD, FAAD
2022 AAD Innovation Academy
JAK inhibitors revolutionize dermatology
Jul 22, 2022
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.